| __timestamp | Gilead Sciences, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 22570000 |
| Thursday, January 1, 2015 | 3426000000 | 24378000 |
| Friday, January 1, 2016 | 3398000000 | 26621000 |
| Sunday, January 1, 2017 | 3878000000 | 28653000 |
| Monday, January 1, 2018 | 4056000000 | 37734000 |
| Tuesday, January 1, 2019 | 4381000000 | 41884000 |
| Wednesday, January 1, 2020 | 5151000000 | 64435000 |
| Friday, January 1, 2021 | 5246000000 | 57483000 |
| Saturday, January 1, 2022 | 5673000000 | 70062000 |
| Sunday, January 1, 2023 | 6090000000 | 52790000 |
| Monday, January 1, 2024 | 6091000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Gilead Sciences, Inc. and Ligand Pharmaceuticals Incorporated have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead Sciences experienced a significant increase of approximately 104% in SG&A expenses, reflecting its expansive growth and strategic investments. In contrast, Ligand Pharmaceuticals saw a more modest rise of around 134%, indicating a steady yet impactful growth strategy.
Gilead's SG&A expenses surged from $2.98 billion in 2014 to $6.09 billion in 2023, highlighting its aggressive market positioning. Meanwhile, Ligand's expenses grew from $22.57 million to $52.79 million, showcasing its focused approach in niche markets. These trends underscore the diverse strategies employed by these pharmaceutical giants in navigating the competitive landscape.
Selling, General, and Administrative Costs: Johnson & Johnson vs Gilead Sciences, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and ImmunityBio, Inc.
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends